| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.16 | 0.3 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |